

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**VOLUNTARY ANNOUNCEMENT
IN RESPECT OF THE LAUNCH APPROVAL FOR
MONA LISA PROSTATE PUNCTURE ROBOT
BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
OF CHINA**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that, iSR’obot Mona Lisa Robotic Transperineal Prostate Biopsy System (“**Mona Lisa**”), a product of Shanghai Intbot Robotics Co., Ltd. (“**Shanghai Intbot**”), a joint venture company in China jointly established by the Company and Biobot Surgical Pte. Ltd., has obtained the approval for launch by the National Medical Products Administration of China.

ABOUT MONA LISA

Mona Lisa is an innovative robotics product in the field of percutaneous puncture, which enables physicians to conduct biopsy sampling more precisely and efficiently; before the procedure, physicians can conduct surgical planning and interactive adjustment through intelligent software; in the course of procedure, a powerful elastic MRI-ultrasound fusion algorithm can guide physicians in real-time, allowing target sites to be easily and accurately sampled regardless of whether they are located in the prostate sharp, base bottom or peripheral belt. The innovative two-point needling approach can minimize the interference of the bones, reduce the incisions of patients, and achieve full prostate coverage; after the procedure, Mona Lisa can generate a complete report containing 3D images and clinical data.

IMPACT ON THE COMPANY

As the first prostate puncture robot obtained the approval in the field of urology in China, Mona Lisa can improve the positive detection rate of patients, reduce manual error and omission diagnostic rate, assisting clinical physicians to complete biopsy puncture surgeries more accurately and efficiently, and at the same time reduce the pain of patients. The product provides more medical options and better conditions for patients requiring prostate biopsy puncture, which will fill the gap in the domestic market for robot-assisted puncture products, marking a new breakthrough of the Group in the field of percutaneous puncture. In the future, we will conduct in-depth research and development of technology and focus on the frontline clinical needs. With the sustaining clinical applications and medical-industrial cooperation, we facilitate the integration of puncture positioning system and multi-module ablation energy platform, so as to build an integrated diagnosis and treatment platform for the benefit of more physicians and patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in shares of the Company.

By Order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 18 May 2023

As at the date of this announcement, the executive director of the Company is Dr. He Chao, the non-executive directors of the Company are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive directors of the Company are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.